Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Allergy Point-Of-Care Testing Market Size, Value And Growth Trends Through 2030

The allergy point-of-care testing market size has experienced significant expansion in recent years. It is projected to increase from $1.33 billion in 2025 to $1.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.8%. Historically, the market’s expansion can be attributed to rising prevalence of allergic disorders globally, increasing clinical awareness of early allergy diagnosis, expansion of immunoassay technologies in diagnostics, growth in hospital based laboratory testing infrastructure, and increasing pediatric allergy cases.

The allergy point-of-care testing market is anticipated to experience swift expansion over the coming years. This market is projected to reach $2.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. The expansion during this forecast period stems from factors such as broader adoption of point-of-care diagnostics, advancements in personalized medicine approaches for allergy management, a surging need for rapid home-based testing solutions, the incorporation of AI-enabled diagnostic interpretation tools, and the increasing move towards decentralized healthcare and expanded outpatient services. Key trends anticipated for the forecast period encompass a greater uptake of rapid immunoglobulin E based allergy diagnostics, a growing preference for portable point-of-care testing devices, the expansion of decentralized allergy screening in primary care environments, an increase in immunoassay-based rapid allergy detection kits, and the deeper integration of digital health platforms into allergy testing workflows.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample_request?id=25183021&type=smp

Allergy Point-Of-Care Testing Market Development Factors: Which Trends Are Supporting Demand?

The rising incidence of allergic conditions is anticipated to significantly propel the expansion of the allergy point of care testing market. Allergic conditions are classified as immune system disorders where the body overreacts to otherwise harmless substances, manifesting symptoms such as sneezing, skin rashes, and respiratory distress. The prevalence of these conditions is increasing, largely due to heightened exposure to environmental allergens like pollen, dust, and pollution, which trigger exaggerated immune responses in susceptible individuals. Allergy point of care testing facilitates the swift and convenient detection of specific allergens, thereby empowering healthcare providers to promptly identify triggers, formulate personalized treatment strategies, and effectively help individuals manage and mitigate the impact of allergic conditions. For instance, in November 2025, Asthma Australia, an Australia-based non-profit organization, reported that 322 women died from asthma last year, which was more than double the 156 men. This trend has remained consistent since 2023, with half of the total 478 deaths occurring among women aged 75 and over. Consequently, the increasing occurrence of allergic conditions is a primary factor driving the growth of the allergy point of care testing market. The escalating healthcare expenditure is projected to fuel the growth of the allergy point-of-care testing market moving forward. Healthcare expenditure encompasses the total financial resources spent by governments, private organizations, and individuals on health services, medical products, public health programs, and essential healthcare infrastructure. This spending is growing due to the escalating demand for medical services, as more patients require consultations, treatments, and diagnostic evaluations, leading to higher overall healthcare costs. Increased healthcare expenditure supports the growth of allergy point-of-care (POC) testing by enabling investments in sophisticated diagnostic technologies, facilitating rapid testing close to patient care sites, reducing reliance on centralized laboratories, and enhancing overall efficiency and healthcare outcomes. For example, in January 2026, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that in 2024, National Health Expenditure (NHE) rose by 7.2% to $5.3 trillion, averaging $15,474 per person, and accounted for 18.0% of the Gross Domestic Product (GDP). Therefore, the expanding financial outlay on healthcare is a significant impetus behind the growth of the allergy point-of-care testing market.

Allergy Point-Of-Care Testing Market Segments: Where Are The Largest Growth Opportunities?

The allergy point-of-care testing market covered in this report is segmented –

1) By Product Type: Rapid Specific Immunoglobulin E Kits, Skin Prick Testing Kits, Rapid Anaphylaxis Kits, Sample Collection Devices, Analyzers

2) By Sample Type: Blood, Serum Or Plasma, Fingerstick Whole Blood

3) By Allergen Type: Food Allergens, Environmental Allergens, Drug And Insect Venom Allergens

4) By Application Focus: Primary Care Triage, Pediatric Clinic Workups, Emergency Care Support, Occupational Health Screening, Pharmacy Led Testing

5) By End User: Specialty Clinics, Hospitals, Retail Pharmacies, Occupational Health Providers, Direct To Consumer

Subsegments:

1) By Rapid Specific Immunoglobulin E Kits: Food Allergy Kits, Inhalant Allergy Kits, Drug Allergy Kits, Environmental Allergy Kits

2) By Skin Prick Testing Kits: Standard Allergen Panels, Custom Allergen Panels, Pediatric Testing Kits, Adult Testing Kits

3) By Rapid Anaphylaxis Kits: Epinephrine Auto Injectors, Immediate Reaction Detection Kits, Allergic Response Monitoring Kits, Emergency Response Kits

4) By Sample Collection Devices: Blood Collection Devices, Saliva Collection Devices, Skin Prick Sampling Devices, Capillary Sampling Devices

5) By Analyzers: Immunoassay Analyzers, Chemiluminescence Analyzers, Integrated Analyzer Systems, Portable Point Of Care Analyzers

Allergy Point-Of-Care Testing Market Transformation Trends: Which Innovations Are Driving Change?

Within the allergy point-of-care testing market, major companies are concentrating on developing innovative products, specifically semi-quantitative point-of-care diagnostic devices, to deliver rapid and accurate allergy test results in clinical settings. These semi-quantitative devices are instruments designed to measure approximate levels of specific biomarkers, such as IgE, directly at the clinic, providing swift and reliable outcomes. This capability allows healthcare providers to quickly assess the severity of allergic responses and make immediate, informed treatment decisions, eliminating the wait associated with traditional laboratory tests. For example, in June 2024, Kenota Health, a Canada-based medical technology company, secured U. S. Food and Drug Administration (FDA) clearance and a CLIA waiver for its Kenota 1 Total IgE test system, enabling its deployment in point-of-care clinical environments. The Kenota 1 system is a semi-quantitative diagnostic device that measures total IgE levels from a minimal fingerstick blood sample, delivering results in under 30 minutes with automated operation, a significant improvement over traditional laboratory IgE tests that require venous blood draws and several days for results. This system is engineered for rapid, in-office allergy assessment, featuring a small blood volume requirement of 4.5 microliters per test, easy-to-use operation, and the capacity to run 15–60 tests per session. Its applications include supporting the diagnosis of IgE-mediated allergic disorders and empowering clinicians to make immediate patient care decisions, thereby streamlining allergy management and improving patient outcomes.

Allergy Point-Of-Care Testing Market Major Participants And Competitive Dynamics

Major companies operating in the allergy point-of-care testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Hitachi Chemical Diagnostic Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Eurofins Scientific SE, bioMérieux SA, Quidel Corporation, EUROIMMUN Medizinische Labordiagnostika AG, R-Biopharm AG, HOB Biotech Group Corp. Ltd., Hycor Biomedical Inc., Omega Diagnostics Ltd, Lincoln Diagnostics Inc., Alerchek Inc., Abionic SA, Kenota Health Inc.

Access The Complete Allergy Point-Of-Care Testing Market Report:

https://www.thebusinessresearchcompany.com/report/allergy-point-of-care-testing-market-report

Allergy Point-Of-Care Testing Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the allergy point-of-care testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allergy point-of-care testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.